Timosaponin BII(Synonyms: Prototimosaponin A III)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Timosaponin BII (Synonyms: Prototimosaponin A III) 纯度: 98.63%

Timosaponin BII (Prototimosaponin A III) 是在知母根茎中发现的一种甾体皂苷。Timosaponin BII 具有神经保护、抗炎和抗氧化活性。

Timosaponin BII(Synonyms: Prototimosaponin A III)

Timosaponin BII Chemical Structure

CAS No. : 136656-07-0

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1783 In-stock
5 mg ¥880 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Timosaponin BII 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Glycoside Compound Library
  • Traditional Chinese Medicine Monomer Library

生物活性

Timosaponin BII (Prototimosaponin A III) is a steroid saponin found in the rhizomes of Anemarrhena asphodeloides. Timosaponin BII has neuronal protective, anti-inflammatory and antioxidant activities[1][2].

体外研究
(In Vitro)

Timosaponin BII is a steroidal glycoside separated from Zhi Mu, is found to have the inhibitory activity against the proliferation of HL-60 (leukemic), Hela (cervix), HepG2 and Bel-7402 (liver), HT-29 (colon), and MDA-MB-468 (breast) human carcinoma cell lines with an IC50 value of 15.5 μg/mL in the HL-60 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Rat retinas in model group and vehicle control group manifest an apparent up-regulation of BACE1 expression. Meanwhile, the level of malonaldehyde (MDA), Aβ1-40 and β-CTF are increased. However, when comparing with the vehicle control group, the retinas in Timosaponin-BII treated group showed significantly less BACE1 and accumulated less Aβ1-40 or β-CTF. It also showed significantly decreased level of MDA and prolonged partial thromboplastin time[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

921.07

Formula

C45H76O19

CAS 号

136656-07-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

H2O : 100 mg/mL (108.57 mM; Need ultrasonic)

DMSO : 100 mg/mL (108.57 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0857 mL 5.4285 mL 10.8569 mL
5 mM 0.2171 mL 1.0857 mL 2.1714 mL
10 mM 0.1086 mL 0.5428 mL 1.0857 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.71 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.71 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.71 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Guo J, et al. Cytotoxic activities of chemical constituents from rhizomes of Anemarrhena asphodeloides and their analogues. Arch Pharm Res. 2015;38(5):598-603.

    [2]. Huang JF, et al. Timosaponin-BII inhibits the up-regulation of BACE1 induced by ferric chloride in rat retina. BMC Complement Altern Med. 2012 Oct 22;12:189.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务